Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01891019 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in the Treatment of Chronic Plaque Psoriasis.
A Phase 2 study of Psoriasis, Plaque-type, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01891019 is a Phase 2 study of Psoriasis, Plaque-type that has completed, run by Wake Forest University. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01891019, a Phase 2 study of Psoriasis, Plaque-type, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to obtain information on the effectiveness of thalidomide in psoriasis.
Conditions Studied
Interventions
- DRUG Thalidomide oral
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences Dermatology - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2003-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01891019
The ClinicalTrials.gov registry entry for NCT01891019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis, Plaque-type appearing as the primary indexed condition, and to 1 intervention - of which Thalidomide oral is the first listed.
NCT01891019 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01891019 about?
NCT01891019 is a clinical study titled "Thalidomide in the Treatment of Chronic Plaque Psoriasis.". The objective of this study is to obtain information on the effectiveness of thalidomide in psoriasis.
What is the current status of trial NCT01891019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2003-04. Estimated completion is 2009-06.
What conditions does trial NCT01891019 study?
This clinical trial studies the following conditions: Psoriasis, Plaque-type.
What interventions are being tested in trial NCT01891019?
The interventions under investigation include: Thalidomide oral (DRUG).
Who is sponsoring clinical trial NCT01891019?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01891019 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.